Labviva has raised $55.0M in total across 4 funding rounds.
Labviva's investors include Glasswing Ventures, Jennifer Lum.
Labviva is an AI-powered digital purchasing platform designed for the life sciences industry, unifying fragmented procurement processes by connecting researchers, procurement teams, and suppliers of reagents, chemicals, consumables, and instrumentation.[1][2][3][6] It integrates seamlessly with existing systems like SAP Ariba, JAGGAER, Oracle Procurement Cloud, Microsoft Dynamics 365, and Coupa, delivering real-time insights into supply chains, inventory management, and spend analytics to cut costs by an average of 20% and save thousands of human hours monthly.[2][3][6] Serving pharmaceutical companies, educational research labs, and biopharma organizations, Labviva solves inefficiencies in manual purchasing that hinder innovation, enabling faster research while ensuring compliance and sustainability goals.[1][2][6] Founded in 2017 and based in Boston, the company has shown strong growth, doubling revenue and tripling transaction volumes recently, bolstered by a $25M Series B round bringing total funding to $55M.[2]
Labviva was founded in 2017 by Siamak Baharloo (CEO) and Nicholas Rioux, drawing from their extensive experience in procurement and eCommerce at life sciences giants like ThermoFisher Scientific, MilliporeSigma, and Sartorius.[2][3] The idea emerged from firsthand frustration with inefficient procurement and outsourced inventory management that slowed scientific innovation, prompting the duo to build an AI-native platform tailored to life sciences needs.[3][5] Early traction came from addressing these pain points, leading to adoption by leading pharmaceutical and research labs; pivotal growth accelerated over the past year with revenue doubling, transaction volumes tripling, and the Series B led by 53 Stations, which added Jason Pritzker to the board.[2]
Labviva rides the wave of AI adoption in life sciences procurement, a sector ripe for disruption due to fragmented supply chains and high manual overhead amid booming R&D demands from pharma and biotech.[2][3][5] Timing aligns with post-pandemic supply chain pressures and sustainability mandates, where AI optimizes inventory to cut waste and speed innovation—much like Uber or Amazon transformed B2C commerce.[7] Market forces favoring Labviva include explosive growth in life sciences spending and investor interest in AI-healthtech intersections, positioning it to influence the ecosystem by standardizing procurement, fostering supplier diversity, and freeing scientists for breakthroughs.[2][6] Competitors like Opentrons (lab automation) and Albert (materials AI) focus on hardware or niche R&D, but Labviva's end-to-end platform uniquely bridges procurement gaps.[1]
Labviva is poised for scaled expansion, leveraging its $55M funding, new board expertise from 53 Stations and The Pritzker Organization, and AI innovations like Smart Suppliers to enter new markets and deepen integrations.[2][3] Trends like AI-driven supply chain resilience and regulatory pushes for efficiency will propel growth, potentially capturing more of the massive life sciences procurement market. Its influence may evolve from cost-cutter to indispensable R&D accelerator, unifying the supply chain as fragmented processes yield to intelligent platforms—echoing its founding mission to empower science over admin.[3][6]
Labviva has raised $55.0M across 4 funding rounds. Most recently, it raised $25.0M Series B in January 2025.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jan 1, 2025 | $25.0M Series B | Glasswing Ventures, Jennifer Lum | |
| Mar 1, 2023 | $20.0M Series A | Glasswing Ventures, Jennifer Lum | |
| Jun 1, 2021 | $8.0M Seed | Glasswing Ventures, Jennifer Lum | |
| Apr 1, 2019 | $2.0M Seed | Glasswing Ventures, Jennifer Lum |
